Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 12/20 | 0.37 |
| ▸ | ADORA1 | P30542 | 8/20 | 0.37 |
| ▸ | PI4KA | P42356 | 10/20 | 0.34 |
| ▸ | PI4K2B | Q8TCG2 | 10/20 | 0.34 |
| ▸ | PI4K2A | Q9BTU6 | 10/20 | 0.34 |
| ▸ | PI4KB | Q9UBF8 | 10/20 | 0.34 |
| ▸ | ADORA2B | P29275 | 4/20 | 0.34 |
| ▸ | EGFR | P00533 | 1/20 | 0.33 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.32 |
| ▸ | YTHDC1 | Q96MU7 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | THRB | P10828 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1683802 | 0.78 | ADORA2A (0.35) | ADORA2AADORA1PI4KAPI4K2BPI4K2A | |
| SCHEMBL667204 | 0.77 | ADORA2A (0.62) | ADORA2AADORA1PI4KAPI4K2BPI4K2A | |
| SCHEMBL16949893 | 0.75 | ADORA2A (0.37) | ADORA2AADORA1PI4KAPI4K2BPI4K2A | |
| SCHEMBL3857168 | 0.75 | ADORA1 (0.60) | ADORA2AADORA1PI4KAPI4K2BPI4K2A | |
| SCHEMBL320849 | 0.75 | ADORA2A (0.41) | ADORA2AADORA1PI4KAPI4K2BPI4K2A | |
| SCHEMBL25325575 | 0.75 | ADORA2A (0.33) | ADORA2AADORA1PI4KAPI4K2BPI4K2A | |
| SCHEMBL15829723 | 0.75 | ADORA2A (0.37) | ADORA2AADORA1PI4KAPI4K2BPI4K2A | |
| SCHEMBL1868819 | 0.75 | FDPS (0.44) | ADORA2AADORA1PI4KAPI4K2BPI4K2A | |
| SCHEMBL16949944 | 0.75 | ADORA2A (0.37) | ADORA2AADORA1PI4KAPI4K2BPI4K2A | |
| SCHEMBL723948 | 0.75 | ADORA2A (0.34) | ADORA2AADORA1PI4KAPI4K2BPI4K2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102382871-A | Improved method for producing 5'-flavor nucleotide | SHANGHAI FUCHANG TECHNOLOGY CO LTD | 2012-03-21 | — | — | CN | disclosed |
| CN-100575487-C | A kind of method of production 5 '-flavour nucleotide | UNIV FUDAN | 2009-12-30 | — | — | CN | disclosed |
| CN-101063126-A | Method for producing 5'-flavour development nucleic acid | UNIV FUDAN (CN) | 2007-10-31 | — | — | CN | disclosed |
| US-20070160981-A1 | VIRAL PROTEASE | NATIONAL HEALTH RESEARCH INSTITUTES (TW) | 2007-07-12 | — | — | US | disclosed |
| US-6589941-B1 | Preventing or reducing formation of resistance in cytostatic treatment comprising combining BVDU, a salt thereof or BVDU in protected form or in prodrug form with at least one cytostatic agent in order to prevent or reduce the formation | RESPROTECT GMBH (DE) | 2003-07-08 | — | — | US | disclosed |
| EP-0806956-B1 | USE OF 5'SUBSTITUTED NUCLEOSIDES TO PROVIDE RESISTANCE IN CYTOSTATIC TREATMENT | RESPROTECT GMBH (DE) | 2002-08-28 | — | — | EP | disclosed |
| EP-0806956-A1 | USE OF 5'SUBSTITUTED NUCLEOSIDES TO PROVIDE RESISTANCE IN CYTOSTATIC TREATMENT AND MEDICAMENTS CONTAINING SAID NUCLEOSIDES | FRAUNHOFER-GESELLSCHAFT ZUR FÖRDERUNG DER ANGEWANDTEN FORSCHUNG E.V. (DE) | 1997-11-19 | — | — | EP | disclosed |
| WO-1996023506-A1 | USE OF 5'SUBSTITUTED NUCLEOSIDES TO PROVIDE RESISTANCE IN CYTOSTATIC TREATMENT AND MEDICAMENTS CONTAINING SAID NUCLEOSIDES | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. (DE) | 1996-08-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070160981-A1 | VIRAL PROTEASE | XPNPEP1, PREP, XPNPEP2 | ADORA2A 4805/4885ADORA1 4653/4885PI4KA 1774/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.